FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international family stem cell bank and the largest bank in Europe, announces that Marc Waeterschoot has stepped down as Non-Executive Director for personal reasons. Mr. Waeterschoot, co-founder of the Company, has been actively involved in Cryo-Save for over 12 years and will remain a shareholder in the Company. read more
Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension. The start of the study follows Amakem’s receipt of Investigational New Drug Application (IND) approval from the United States Food and Drug Administration (FDA). AMA0076 is a highly potent ROCK inhibitor and is based on Amakem’s ‘Localized Drug Action’ platform, which generates novel kinase inhibitors that minimize the risk of systemic as well as local side effects such as hyperemia. read more
Whether you have an increased risk of developing type 2 diabetes, in the future may be derived from the composition of your intestinal flora. That according to new metagenomics research of an international consortium of scientists, including Jeroen Raes, connected to VIB and Vrije Universiteit Brussel. Metagenomics is the study of the genetic material of complete ecosystems, in this case the human intestine. This study appears in the leading journal Nature. read more
Trinean, the leading provider of microfluidic spectrophotometry platforms, today announced that its DropSense96® droplet reader has been chosen by Avacta for High Throughput analysis of their purified Affimer proteins. read more
Multiplicom, a molecular diagnostics company specializing in innovative molecular genetics tests based on massively parallel sequencing (MPS) today announces that it is launching new genomic and somatic mutation detection kits based on its proprietary MASTR technology. read more
Ablynx [Euronext Brussels: ABLX] today announced that Dr Roger Perlmutter and Dr Russell G. Greig will be proposed as Independent Non-Executive Directors at the Company's forthcoming Extraordinary General Meeting of its shareholders at the beginning of November 2012. read more